Opendata, web and dolomites

Vacc-iNTS SIGNED

Advancing a GMMA-based vaccine against invasive non-typhoidal salmonellosis through Phase 1 trial in Europe and sub-Saharan Africa

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 Vacc-iNTS project word cloud

Explore the words cloud of the Vacc-iNTS project. It provides you a very rough idea of what is the project "Vacc-iNTS" about.

preclinical    resource    gap    invasive    gmma    bacteria    generate    modules    vacc    antigens    trials    experts    collaborative    saharan    countries    levels    drive    immunogenic    enteritidis    advocacy    manufacturing    antibody    tackling    accelerate    olds    20    disease    resistance    followed    infectious    trial    genetically    outer    antibiotic    epidemiological    serotypes    rapid    data    antibodies    sero    sub    animals    academia    strains    integration    blebs    advancing    diagnosis    transcriptomics    bridges    scalable    difficult    ssa    released    typhimurium    deployment    lots    industry    proposes    safety    bactericidal    africa    263    typhoidal    limited    membrane    gmp    fatality    settings    ints    suited    generalized    modified    clinical    proof    biology    network    african    cellular    rate    profit    vaccine    advocate    healthy    sonnei    poor    shigella    immunogenicity    stage    salmonellosis    serum    adults    roadblocks    endemic    strengthen    lt    deaths   

Project "Vacc-iNTS" data sheet

The following table provides information about the project.

Coordinator
SCLAVO VACCINES ASSOCIATION 

Organization address
address: PIAZZA LA LIZZA 7
city: SIENA
postcode: 53100
website: www.sclavo.org/home

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Italy [IT]
 Total cost 0 €
 EC max contribution 6˙871˙188 € (0%)
 Programme 1. H2020-EU.3.1.3. (Treating and managing disease)
 Code Call H2020-SC1-2018-Two-Stage-RTD
 Funding Scheme RIA-LS
 Starting year 2019
 Duration (year-month-day) from 2019-10-01   to  2024-09-30

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    SCLAVO VACCINES ASSOCIATION IT (SIENA) coordinator 1˙152˙311.00
2    THE CHANCELLOR, MASTERS AND SCHOLARS OF THE UNIVERSITY OF OXFORD UK (OXFORD) participant 2˙227˙288.00
3    GSK VACCINES INSTITUTE FOR GLOBAL HEALTH SRL IT (SIENA) participant 1˙576˙515.00
4    THE CHANCELLOR MASTERS AND SCHOLARSOF THE UNIVERSITY OF CAMBRIDGE UK (CAMBRIDGE) participant 545˙942.00
5    THE UNIVERSITY OF LIVERPOOL UK (LIVERPOOL) participant 432˙034.00
6    UNIVERSITA DEGLI STUDI DI SIENA IT (SIENA) participant 341˙017.00
7    KWAME NKRUMAH UNIVERSITY OF SCIENCE AND TECHNOLOGY KUMASI GH (KUMASI) participant 194˙226.00
8    UNIVERSITE OUAGA I PROFESSEUR JOSEPH KI-ZERBO BF (OUAGADOUGOU 03) participant 192˙980.00
9    KENYA MEDICAL RESEARCH INSTITUTE KE (Nairobi) participant 107˙575.00
10    UNIVERSITY OF OTAGO NZ (DUNEDIN) participant 50˙000.00
11    PRINS LEOPOLD INSTITUUT VOOR TROPISCHE GENEESKUNDE BE (ANTWERPEN) participant 31˙296.00
12    MMGH CONSULTING GMBH CH (ZURICH) participant 20˙000.00

Map

 Project objective

Invasive non-typhoidal Salmonellosis (iNTS) is an important emerging Neglected Infectious Disease in resource-poor settings of sub-Saharan Africa (sSA). No vaccine is currently available. Estimated 263,000 iNTS deaths per year in <5 year olds, a 20% case fatality rate, difficult diagnosis and increasing antibiotic resistance strongly advocate for rapid development of an effective vaccine. Vacc-iNTS bridges the gap between preclinical and early clinical development of a novel vaccine against iNTS, based on GMMA (Generalized Modules for Membrane Antigens) from the most common African iNTS serotypes (Typhimurium and Enteritidis). The highly cost-effective GMMA-technology, developed by partner 2, is based on outer membrane blebs released by genetically modified bacteria. Clinical proof-of-concept for the GMMA-technology was achieved with a Shigella sonnei vaccine in European and African adults. In animals, iNTS-GMMA were highly immunogenic and induced antibodies with bactericidal activity against African iNTS strains. Simple, robust and scalable manufacturing processes for iNTS-GMMA, suited for sSA, have been developed. Vacc-iNTS proposes GMP manufacturing of clinical lots followed by a two-stage Phase 1 trial in healthy European and African adults to investigate safety and immunogenicity of the iNTS-GMMA vaccine. Analysis include serum antibody levels and functionality, cellular responses, transcriptomics and data integration through a systems biology approach. Sero-epidemiological analysis will be conducted to provide essential data for future Phase 2 and 3 trials. Vacc-iNTS will also strengthen a collaborative network of iNTS experts from academia, industry and non-profit including partners from disease-endemic countries of sSA. The network will generate data to accelerate further vaccine development, enhance awareness, drive advocacy and vaccine deployment in limited-resources disease-endemic countries, tackling major roadblocks in advancing a vaccine against iNTS.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "VACC-INTS" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "VACC-INTS" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.1.3.)

GACD (2019)

Global Alliance for Chronic Diseases Secretariat

Read More  

INTE-AFRICA (2019)

Integrating and decentralising diabetes and hypertension services in Africa

Read More  

SBR (2020)

SMART BONE REGENERATION

Read More